Toyohiro Yamada

Ogaki, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Real-World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study.

Real-World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: February 17, 2026

Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan.

Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan.

Journal: Cancers

Published: June 19, 2024

Utility and safety of robot-assisted radical cystectomy in older patients with bladder cancer.

Utility and safety of robot-assisted radical cystectomy in older patients with bladder cancer.

Journal: Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy

Published: August 22, 2023

Case of extragonadal germ cell tumor mimicking left adrenal tumor.

Case of extragonadal germ cell tumor mimicking left adrenal tumor.

Journal: Urology case reports

Published: June 15, 2023

Biochemical recurrence after chemohormonal therapy followed by robot-assisted radical prostatectomy in very-high-risk prostate cancer patients.

Biochemical recurrence after chemohormonal therapy followed by robot-assisted radical prostatectomy in very-high-risk prostate cancer patients.

Journal: Journal of robotic surgery

Published: April 03, 2023

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer.

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer.

Journal: Life (Basel, Switzerland)

Published: March 22, 2023

The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.

The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.

Journal: Cancers

Published: December 26, 2022

Efficacy and Safety of the "Trisection Method" Training System for Robot-Assisted Radical Cystectomy at a Single Institution in Japan.

Efficacy and Safety of the "Trisection Method" Training System for Robot-Assisted Radical Cystectomy at a Single Institution in Japan.

Journal: Current oncology (Toronto, Ont.)

Published: October 20, 2022

Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study.

Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study.

Journal: Biomedicines

Published: August 01, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026